← board
DBVTF
distress 5/10 · elevated risk$4.260%today-11% from 52w high
Lead: peanut allergy in children aged 4-7 years
Revenue
pre-revenue
Liquidity
$175M
Runway
1.0 yrs
Shares 1y
+116%
Price & events
+4259900.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
-0.9%
3M
+4259900.3%
6M
+4259900.3%
1Y
+52.1%
2Y
+2.4%
5Y
+2.4%
All
Overview
- Market Cap
- $1.26B
- Volume
- 0
- 52 Week Range
- $0.00 – $4.80
- Total Shares
- 296.06M
- Float Shares
- 176.27M
- % Held by Insiders
- 0.13%
- % Held by Institutions
- 51.93%
- Beta
- -0.21
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- third quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)VIASKIN Peanut Patch · Planned BLA submission for VIASKIN Peanut PatchSEC 8-K
- 2026-07-16Confirmed 100%earningsEarningsEarnings releaseyahoo
- first half of 2026regulatory submissionFiled (NDA/BLA)VIASKIN Peanut Patch · BLA submission expected in first half of 2026SEC 8-K
- Q4 2025readoutPhase 3Viaskin Peanut Patch · Topline results expectedSEC 8-K
- second quarter of 2025trial initiationsecondaryViaskin Peanut Patch · COMFORT Toddlers safety study initiationSEC 8-K
- 2024-10-22fda agreementViaskin Peanut Patch · FDA guidance on Accelerated Approval pathway for toddlers 1-3 yearsSEC 8-K
- August 2024enrollment completesecondaryPhase 3Viaskin Peanut Patch · Patient screening completed for VITESSE Phase 3 trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — peanut allergy in children aged 4-7 years
- none identified
Recent news
- 2026-07-14DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 - markets.businessinsider.com
- 2026-06-08DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 - markets.businessinsider.com
- 2026-06-05DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
- 2026-06-03DBV Technologies Announces the Results of its 2026 Combined General Meeting - markets.businessinsider.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.